Differential expression of ISG20 in chronic hepatitis B patients and relation to interferon-alpha therapy response

Journal of Medical Virology

Volumn 85, Issue 9, 2013, Pages 1506-1512

  Lu, Xi ^a   Qin, Bo ^a   Ma, Qian ^a   Yang, Chun ^a   Gong, Xue Yan ^a   Chen, Li Min ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic hepatitis B; Interferon , immunohistochemistry; Interferon stimulated gene 20

Indexed keywords

ALPHA2A INTERFERON; DNA; HEPATITIS B SURFACE ANTIGEN; ISG20 PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MALE; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

CHRONIC HEPATITIS B; INTERFERON-Α, IMMUNOHISTOCHEMISTRY; INTERFERON-STIMULATED GENE 20;

ADULT; BIOLOGICAL MARKERS; BIOPSY; DNA, VIRAL; EXONUCLEASES; FEMALE; GENE EXPRESSION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; INTERFERON-ALPHA; LIVER; MALE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 84880326337     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23610     Document Type: Article

References (23)

1. Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293.
2. Blum HE. 1993. Hepatitis B virus: Significance of naturally occurring mutants. Intervirology 35:40-50.
3. Eckert M, Meek SE, Ball KL. 2006. A novel repressor domain is required for maximal growth inhibition by the IRF-1 tumor suppressor. J Biol Chem 281:23092-23102.
4. Espert L, Rey C, Gonzalez L, Degols G, Chelbi-Alix MK, Mechti N, Gongora C. 2004. The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation. Oncogene 23:4636-4640.
5. Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, Pol S. 2001. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 32:904-909.
6. Gongora C, David G, Pintard L, Tissot C, Hua TD, Dejean A, Mechti N. 1997. Molecular cloning of a new interferon-induced PML nuclear body-associated protein. J Biol Chem 272:19457-19463.
7. Gongora C, Degols G, Espert L, Hua TD, Mechti N. 2000. A unique ISRE, in the TATA-less human Isg20 promoter, confers IRF-1-mediated responsiveness to both interferon type I and type II. Nucleic Acids Res 28:2333-2341.
8. Hao Y, Yang D. 2008. Cloning, eukaryotic expression of human ISG20 and preliminary study on the effect of its anti-HBV. J Huazhong Univ Sci Technolog Med Sci 28:11-13.
9. Horio T, Murai M, Inoue T, Hamasaki T, Tanaka T, Ohgi T. 2004. Crystal structure of human ISG20, an interferon-induced antiviral ribonuclease. FEBS Lett 577:111-116.
10. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA, Aldovini A. 2003. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 9:191-197.
11. Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. 2008. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 82:1665-1678.
12. Kao JH. 2007. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 37:S47-S54.
13. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107.
14. Lengyel P. 1993. Tumor-suppressor genes: News about the interferon connection. Proc Natl Acad Sci USA 90:5893-5895.
15. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. 2008. Chronic hepatitis B guideline working party of the asian-pacific association for the study of the liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2:263-283.
16. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. 2008. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48:200-207.
17. Mattei MG, Tissot C, Gongora C, Mechti N. 1997. Assignment of ISG20 encoding a new interferon-induced PML nuclear body-associated protein, to chromosome 15q26 by in situ hybridization. Cytogenet Cell Genet 79:286-287.
18. Nguyen LH, Espert L, Mechti N, Wilson DM, III. 2001. The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro. Biochemistry 40:7174-7179.
19. Wieland SF, Vega RG, Müller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV. 2003. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 77:1227-1236.
20. Wieland S, Thimme R, Purcell RH, Chisari FV. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101:6669-6674.
21. Xiao C, Qin B, Chen L, Liu H, Zhu Y, Lu X. 2011. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J Viral Hepat 19:e1-e10.
22. Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action. Cell 72:753-765.
23. Zhu Y, Qin B, Xiao C, Lu X, Chen L. 2012. Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients. Dig Dis Sci 57:2355-2361.